Ken Griffin’s Citadel Is Piling Into These 5 Stocks

3. Moderna, Inc. (NASDAQ:MRNA) CALL

Number of Hedge Fund Holders: 43  

Percentage Increase in Stake During Q4: 29%

Moderna, Inc. (NASDAQ:MRNA) operates as a biotech firm. Hedge funds have been offloading the stock in recent months as the pandemic wanes. At the end of the fourth quarter of 2021, 43 hedge funds in the database of Insider Monkey held stakes worth $3.8 billion in Moderna, Inc. (NASDAQ:MRNA), compared to 49 in the preceding quarter worth $7.3 billion. 

Latest 13F filings show that Citadel owned CALL options on over 3.7 million shares of Moderna, Inc. (NASDAQ:MRNA) worth $955 million at the end of the fourth quarter of 2021. The company has featured in the Citadel portfolio since the first quarter of 2019. 

In its Q2 2021 investor letter, Baillie Gifford, an asset management firm, highlighted a few stocks and Moderna, Inc. (NASDAQ:MRNA) was one of them. Here is what the fund said:

“Among the top contributors to Fund performance in the second quarter was Moderna. Moderna, Inc. (NASDAQ:MRNA) has just reported its first profitable quarter in the company’s history – net income for the most recent quarter was $1.2 billion. It reported revenue of $1.9 billion, an impressive increase compared to $8 million a year ago, driven by the sales of its Covid-19 vaccine. Moderna, Inc. (NASDAQ:MRNA) is expecting to deliver up to 1 billion vaccine doses in 2021 and is in discussions to increase global supply to governments around the world. Our long-term focus remains on the transformational potential of Moderna’s technology and its ability to address different diseases.”